Ticagrelor
Ticagrelor, sold as Brilinta, is an antiplatelet medicine of the P2Y12 inhibitor class. The FDA label lists three uses: making cardiovascular death, heart attack and stroke less likely in people with acute coronary syndrome or a past heart attack; making a first heart attack or stroke less likely in people with coronary artery disease at high risk; and making a stroke less likely after an acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, it can cause significant, sometimes fatal bleeding.
Also called BRILINTA
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1116632; UNII GLH0314RVC; NDA022433, first approved on 2011-07-20 as a new molecular entity (Drugs@FDA record, sponsor ASTRAZENECA). The label read is the AstraZeneca label in openFDA (effective 2026-05-07); two repackager labels were not used. This page records label indications and the class only: no trial result is recorded for the medicine here, and no dose is given.
Trials at a glance
The figures count the 70 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 70
- Phase 3 or 4
- 59
- Recruiting
- 9
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 0 | 5 | 0 | 2 | 7 |
| Phase 2/3 | 0 | 2 | 0 | 0 | 2 |
| Phase 3 | 2 | 13 | 1 | 3 | 19 |
| Phase 4 | 6 | 20 | 1 | 13 | 40 |
| No phase | 1 | 0 | 0 | 1 | 2 |
| All phases | 9 | 40 | 2 | 19 | 70 |
Conditions these trials study
- Acute coronary syndrome
- Coronary artery disease
- Heart attack (myocardial infarction)
- ST-elevation heart attack (STEMI)
- Stroke
- Unstable angina
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Diabetes mellitus
- Stable angina
Sponsors with the most trials
- AstraZeneca
- Deutsches Herzzentrum Muenchen
- Faculty Hospital Kralovske Vinohrady
- Hellenic Cardiovascular Research Society
- LifeBridge Health
About this drug
- Level
- Substance
- Mechanism
- The label says ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation.
Claims and evidence
Context People for whom the US label of ticagrelor (Brilinta) lists an indication: acute coronary syndrome or past heart attack, high-risk coronary artery disease, acute ischemic stroke or high-risk transient ischemic attack
- Recipient
- Adult
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients with acute coronary syndrome or a history of myocardial infarction
- Patients with coronary artery disease at high risk of a first myocardial infarction or stroke
- Patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or high-risk transient ischemic attack
- Excluded
- None stated
The US label of BRILINTA (ticagrelor), in the AstraZeneca version dated 7 May 2026 in openFDA, lists the medicine for lowering the chance of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lists it for lowering the chance of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, and for lowering the chance of stroke in patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, the medicine can cause significant, sometimes fatal bleeding.
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications and the first line of the boxed warning were read; contraindications, doses, interactions and other warnings were not recorded. Labels change: openFDA also lists repackager copies with older text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (9)
-
- Locator
- results[0].indications_and_usage[0], 1.1, sentence 1, fragment 1 of 2
- How it applies
- First indication, first part.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1, sentence 1, fragment 2 of 2
- How it applies
- First indication, second part.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2, sentence 1, fragment 1 of 2
- How it applies
- Second indication, first part.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2, sentence 1, fragment 2 of 2
- How it applies
- Second indication, second part.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.3, sentence 1, fragment 1 of 2
- How it applies
- Third indication, first part.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.3, sentence 1, fragment 2 of 2
- How it applies
- Third indication, second part.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.3, parenthetical
- How it applies
- The stroke severity limit the label gives for the third indication.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], sentence 1
- How it applies
- First line of the boxed warning.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260507.
- Retrieved
- Source effective date
- 2026-05-07
- Source state
- Current
- Version fingerprint
c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context United States approval record NDA022433 for Brilinta (ticagrelor)
- Recipient
- Recipient not specified
- Population
- Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication for the original approval.
- Care setting
- Not stated in the FDA record
- Geography
- United States (decision by the US Food and Drug Administration)
- Life stage
- Not stated in the FDA record
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
The openFDA Drugs@FDA record for New Drug Application NDA022433 (BRILINTA, ticagrelor tablets) lists the original approval as submission ORIG-1, with status date 20 July 2011, classified as Type 1 - New Molecular Entity, with standard review priority. The record names ASTRAZENECA as the sponsor of the application.
Applies to Recipient not specified United States approval record NDA022433 for Brilinta (ticagrelor)
- Certainty method
- Not assessed
- Limitations
- This claim records the original approval and the fields the record gives. The record fetched carries no indication text for the original approval, so the claim does not say what the medicine was approved to treat in 2011; current uses are in the label claim. The record also lists many later supplements. An approval is not a finding about how well the medicine works. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)
- Locator
- results[0].application_number
- How it applies
- The application number of this record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)
- Locator
- results[0].submissions[14].submission_type
- How it applies
- The original submission.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)
- Locator
- results[0].submissions[14].submission_status_date
- How it applies
- The original approval status date, in compact form.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)
- Locator
- results[0].submissions[14].submission_class_code_description
- How it applies
- The submission classification of the original approval.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)
- Locator
- results[0].submissions[14].review_priority
- How it applies
- The review priority of the original approval.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
-
Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)
- Locator
- results[0].sponsor_name
- How it applies
- The application sponsor, as the record writes the name.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
FDA label
Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.
BRILINTA
- Application
- NDA022433
- Labeler
- AstraZeneca Pharmaceuticals LP
- Label version
- Version 56, effective
- Label set id
f7b3f443-e83d-4bf2-0e96-023448fed9a8- Boxed warning
- Yes
- Sections the label has
- Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists acute coronary syndrome or a past heart attack as an indication: Acute coronary syndrome
The US label of BRILINTA (ticagrelor), in the AstraZeneca version dated 7 May 2026 in openFDA, lists the medicine for lowering the chance of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lists it for lowering the chance of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, and for lowering the chance of stroke in patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, the medicine can cause significant, sometimes fatal bleeding.Limitations. This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications and the first line of the boxed warning were read; contraindications, doses, interactions and other warnings were not recorded. Labels change: openFDA also lists repackager copies with older text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 6 efficacy supplement approvals on record.
Registry trials 70
Record details
- Record id
cardio:ticagrelor- Content hash
2d701f022832635cbab9f6e13c1c8e7dcc966ad31e8a1ecaeee1649df4f09f8d